Regeneron Pharmaceuticals, Inc. Release: IL-1 Trap Phase 3 Trial Data Presented at Annual Meeting of American Academy of Allergy, Asthma and Immunology (AAAAI)

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that efficacy and safety data for the Phase 3 clinical trial of Regeneron’s Interleukin-1 (IL-1) Trap (rilonacept) in patients with Cryopyrin-Associated Periodic Syndromes (CAPS) were presented at the 2007 American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting in San Diego, CA. The presentation was made by Dr. Hal Hoffman, Associate Professor of Pediatrics and Medicine, Division of Rheumatology, Allergy, and Immunology at the University of California at San Diego. This is the first presentation of the data at a scientific conference, having been accepted as a late-breaking abstract for the annual meeting.

Back to news